MaaT Pharma Study Highlights Critical Gaps in Third-Line aGvHD Treatments
Event summary
- MaaT Pharma published retrospective data from the CHRONOS study in Bone Marrow Transplantation Journal, evaluating 59 patients with steroid- and ruxolitinib-refractory aGvHD.
- The study reported a 37% GI-overall response rate at Day 28, declining to 22% by Day 56, with a 12-month overall survival rate of 29%.
- CHRONOS data underscores the limited durability and survival benefits of current third-line therapies, setting a benchmark for MaaT013 (Xervyteg®) evaluation.
- The ARES trial results, presented at ASH 2025 and EBMT 2026, showed significantly higher response rates and survival compared to CHRONOS, supporting Xervyteg®'s potential.
- MaaT Pharma aims to use CHRONOS data to support its Marketing Authorization Application for Xervyteg®.
The big picture
The CHRONOS study highlights the severe limitations of current third-line therapies for steroid- and ruxolitinib-refractory aGvHD, emphasizing the need for novel treatments. MaaT Pharma's Xervyteg®, with its promising ARES trial results, positions itself as a potential game-changer in this high-risk patient population. The study's publication sets a contemporary benchmark for regulatory evaluation, underscoring the critical unmet medical need in this area.
What we're watching
- Regulatory Benchmarking
- Whether CHRONOS data will serve as a critical benchmark for regulatory evaluation of Xervyteg® and other innovative therapies in the third-line aGvHD setting.
- Therapeutic Efficacy
- The pace at which MaaT Pharma can translate the ARES trial results into improved patient outcomes and market adoption of Xervyteg®.
- Market Differentiation
- How Xervyteg® will differentiate itself from current off-label therapies and establish itself as a standardized treatment option in the high-risk aGvHD population.
Related topics